Our previous studies also found that primary tumor characteristics maintained their prognostic power as independent variables for survival in metastatic melanoma patients treated with immune checkpoint inhibitors or BRAF and MEK inhibitor combinations [39,40]. Here, BRAF is linked to metastatic melanoma.